Trial | Neuroprogressive & Dementia Network - NHS Tayside Research Update, Spring 2025

The best way to be considered for current or future trials is to join the 'Permission to Contact' scheme for the Neuroprogressive & Dementia Network.  This will allow the research team to access your medical records and check whether you are eligible for studies.  To find out more details please visit https://www.nhsresearchscotland.org.uk/research-areas/dementia-and-neurodegenerative-disease. 

To sign up for the 'Permission to Contact' scheme, please complete the online form https://www.nhsresearchscotland.org.uk/research-areas/dementia-and-neurodegenerative-disease/patient-signup-form. Alternatively you can email tay.ndntayside@nhs.scot or call 01382 423086 to have a paper form sent out.


Current available trials:

 

  • RAPSODI GD 

Remote assessment of Parkinsonism supporting ongoing development of interventions in Gaucher disease

Open to new recruits: Yes

Study Drug: No

Inclusion criteria: Anyone with a diagnosis of Parkinson’s Disease

Participating Scottish sites: Dundee

Website: https://www.parkinsons.org.uk/research/pd-frontline-identifying-genes-people-parkinsons

 

  • PADOVA 

A Phase IIB, randomized, double-blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of intravenous Prasinezumab. 

Open to new recruits: No

Study Drug: Prasinezumab/placebo

Inclusion criteria: >50-85yo, PD diagnosis 6M-3yr at screening, 3m stable treatment

Participating Scottish sites? Dundee 

Website: https://forpatients.roche.com/en/trials/neurodegenerative-disorder/pd/a-study-to-evaluate-the-efficacy-and-safety-of-intraven-35605.html

 

  • LUMA 

The Luminare Study is evaluating the safety and efficacy of a study drug, as compared to a placebo, to see if it may delay the progression of Parkinson’s disease in people who are in the early stage of their condition. 

Open to new recruits: No

Study Drug: BIIB122/placebo

Inclusion criteria: LUMA. 30-80 years old. Diagnosed with Parkinson’s disease within the last 2 years and were at least 30 years old when you were diagnosed.

Participating Scottish sites: Dundee

Website:  https://www.parkinsonsresearchstudies.com/?utm_source=parkinsonsfoundation&utm_medium=vanity&utm_campaign=luminare&utm_term=url&utm_content=luminarepdstudiesdotcom

 

  • BIAL ACTIVATE

Safety and Tolerability of BIA 28-6156 in people with Parkinson's Disease with a pathogenic variant in the Glucocerebrosidase (GBA1) Gene

Open to new recruits: No

Study Drug:  BIA 28-6156

Inclusion Criteria:  Between 30-80 yrs old, diagnosis of PD in last 7 years and a genetic screening to determine if the participant will qualify for the study

Participating Scottish Sites:  Dundee

Website:  https://bial.com/com/our-research/pipeline/bia-28-6156/

 

  • CAN PDP

CANnabidiol for Parkinson’s Disease Psychosis

Open to New recruits:  Yes

Study Drug:  CBD/placebo

Inclusion Criteria:  over 40 years old, experienced symptoms of psychosis for at least 1 month, been taking PD medication for at least 1 month, 

Participating Scottish Sites:  Aberdeen, Dundee, Edinburgh

Website:  https://www.parkinsons.org.uk/research/can-pdp-cannabidiol-cbd-people-parkinsons-who-experience-hallucinations-or-delusions

 

  • PFP:  Parkinson's and Movement Disorders Families Project

Open to New recruits:  Opening very soon

Study Drug:  No

Inclusion Criteria:  Anyone with a PD diagnosis AND  any of the following:

  • patient has a genetic mutation for PD
  • family member (1st/2nd/3rd) with PD or MD (including tremor)
  • symptom onset under 45 years of age

 

  • EJS-ACT-PD Study

    Objective: Accelerate clinical trials in Parkinson’s Disease by evaluating multiple treatments simultaneously

    Design: Multi-Arm, Multi-Stage Trial

    Focus: Regularly analysing several treatments to assess their effectiveness. Effective treatments will continue, while ineffective ones will be replaced with new options, ensuring no delays in the trial process.

    Goal: To speed up the development of effective treatments for Parkinson’s Disease through a flexible and adaptive trial design

     

  • LITE The MJFF LRRK2 Investigative Therapeutics Exchange (LITE) Study

    Objective: To address critical gaps in our knowledge about Parkinson’s Disease (PD) by exploring genetic and biological markers to predict responses to new treatments

    Focus: Investigate whether biological markers differ between people with PD and those without

    •Examine how these markers could predict responses to treatments aimed at slowing or stopping disease progression

    •Study why some people with a genetic risk for PD develop the disease while others with the same risk do not

  • •Collaborate with the Global Parkinson’s Genetics Program (GP2) to study the genetics of PD, involving both people with and without the disease

  • Goal: To improve our understanding of Parkinson’s Disease, develop new technologies and approaches for measuring the disease, and identify potential biomarkers for better diagnosis and treatment

    More information to come...

-For further information of other research studies:  https://bepartofresearch.nihr.ac.uk/